Clinical Trial Update: Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study of tisotumab vedotin (HuMax®-TF-ADC) in solid tumors completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cervix Cancer
• Endometrium Cancer
• Esophagus Cancer
• Lung Cancer
• Ovary Cancer
• Prostate Cancer

Drugs mentioned

• Tisotumab Vedotin (tisotumab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Ovary Cancer, Cervix Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-03-12